Publication | Closed Access

Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats

Metabolic SyndromeLipoprotein Lipase ActivityLipid SynthesisCardiovascular DiseaseBiochemistryMedicineHyperlipidemiaLipoprotein MetabolismHdl Cholesterol LevelsPharmacologyAtherosclerosisDyslipidemiaDrug Discovery